IINO Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Against Inovio Pharmaceuticals, Inc.

Core Viewpoint - A class action has been filed against Inovio Pharmaceuticals, Inc. for allegedly misleading investors regarding the approval process for its CELLECTRA device and the INO-3107 Biologics License Application (BLA) [1] Group 1: Allegations and Issues - The complaint alleges that Inovio failed to disclose deficiencies in the manufacturing of its CELLECTRA device [1] - It is claimed that Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024 due to these manufacturing issues [1] - The company reportedly lacked sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review [1] Group 2: Impact on Stock Price - Following a press release on August 8, 2024, revealing a delay in the INO-3107 BLA submission to mid-2025, Inovio's stock price fell by $0.27 per share, or 3.1%, closing at $8.44 per share on August 9, 2024 [1] - On December 29, 2025, after announcing that the FDA accepted the INO-3107 BLA on a standard review timeline, Inovio's stock price dropped by $0.56 per share, or 24.45%, closing at $1.73 per share [1] Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Inovio, with a deadline to submit papers to the court by April 7, 2026 [1] - The lead plaintiff will represent other class members in directing the litigation, but participation is not required for recovery [1]